NASDAQ:IRIX - IRIDEX Stock Price, Forecast & News

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

IRIDEX Co. (NASDAQ:IRIX) announced its quarterly earnings results on Thursday, November, 7th. The medical equipment provider reported ($0.13) EPS for the quarter, beating the Zacks' consensus estimate of ($0.18) by $0.05. The medical equipment provider had revenue of $10.66 million for the quarter, compared to analyst estimates of $10.08 million. IRIDEX had a negative net margin of 23.42% and a negative return on equity of 37.78%. View IRIDEX's Earnings History.

IRIDEX is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for IRIDEX.

IRIDEX issued an update on its fourth quarter 2019 After-Hours earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11.6-11.8 million, compared to the consensus revenue estimate of $10.88 million.

News coverage about IRIX stock has trended positive on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IRIDEX earned a news impact score of 2.6 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for IRIDEX.

IRIDEX saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 78,800 shares, a decline of 12.0% from the January 15th total of 89,500 shares. Based on an average daily volume of 70,900 shares, the short-interest ratio is currently 1.1 days. Approximately 0.7% of the company's stock are sold short. View IRIDEX's Current Options Chain.

Some companies that are related to IRIDEX include Soleno Therapeutics (SLNO), Fonar (FONR), Edap Tms (EDAP), BioSig Technologies (BSGM), Second Sight Medical Products (EYES), Fc Global Realty (FCRE), electroCore (ECOR), Helius Medical Technologies (HSDT), Precision Optics (PEYE), ENDRA Life Sciences (NDRA), Digirad (DRAD), Vaso (VASO), Non-Invasive Monitoring Systems (NIMU), Reshape Lifesciences (RSLS) and Viveve Medical (VIVE).

Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include SCYNEXIS (SCYX), NovaBay Pharmaceuticals (NBY), Agile Therapeutics (AGRX), CTI BioPharma (CTIC), Gilead Sciences (GILD), Trevena (TRVN), AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Capstone Turbine (CPST) and Fate Therapeutics (FATE).

IRIDEX's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.43%), Isthmus Partners LLC (1.54%), Perkins Capital Management Inc. (0.39%), Gabelli Funds LLC (0.11%) and Blair William & Co. IL (0.09%). Company insiders that own IRIDEX stock include Associates & Paragon A Paragon, Robert Earle Grove, Romeo R Dizon, Scott Shuda and William M Moore. View Institutional Ownership Trends for IRIDEX.

IRIX stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL and Gabelli Funds LLC. View Insider Buying and Selling for IRIDEX.

IRIX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Isthmus Partners LLC and Perkins Capital Management Inc.. Company insiders that have bought IRIDEX stock in the last two years include Associates & Paragon A Paragon, Robert Earle Grove, Scott Shuda and William M Moore. View Insider Buying and Selling for IRIDEX.

Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IRIX stock can currently be purchased for approximately $3.26.

IRIDEX has a market capitalization of $44.92 million and generates $42.60 million in revenue each year. The medical equipment provider earns $-12,810,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. View Additional Information About IRIDEX.

The official website for IRIDEX is http://www.iridex.com/.

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]